BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36854522)

  • 1. Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting.
    Tamiya A; Tamiya M; Inagaki Y; Taniguchi Y; Nakao K; Matsuda Y; Kawamura T; Kunimasa K; Inoue T; Nishino K; Okishio K
    Anticancer Res; 2023 Mar; 43(3):1325-1330. PubMed ID: 36854522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
    Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
    Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
    Tamiya M; Tamiya A; Yamadori T; Nakao K; Asami K; Yasue T; Otsuka T; Shiroyama T; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Kawase I; Hirashima T
    Med Oncol; 2013; 30(3):676. PubMed ID: 23925664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
    Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
    J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
    Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
    Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.
    Kubota T; Okano Y; Sakai M; Takaoka M; Tsukuda T; Anabuki K; Kawase S; Miyamoto S; Ohnishi H; Hatakeyama N; Machida H; Urata T; Yamamoto A; Ogushi F; Yokoyama A
    Anticancer Res; 2016 Jan; 36(1):307-12. PubMed ID: 26722058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
    Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
    Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
    Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A
    Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
    Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
    Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer.
    Saito Y; Takekuma Y; Shinagawa N; Sugawara M
    Support Care Cancer; 2022 May; 30(5):4081-4088. PubMed ID: 35066667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322.
    Zenke Y; Niho S; Umemura S; Ishihara M; Seki N; Nogami N; Hosomi Y; Shimokawa T; Tokito T; Goto Y; Miura Y; Saito H; Hida N; Ikeda S; Tanaka H; Furuya N; Misumi T; Yamanaka T; Ohe Y; Okamoto H
    Lung Cancer; 2020 Aug; 146():182-188. PubMed ID: 32559454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426.
    Ichikawa Y; Seki N; Honda T; Sakugawa M; Hosokawa S; Bessho A; Agemi Y; Shimokawa T; Otani S; Nakahara Y; Naoki K; Yomota M; Hosomi Y; Takiguchi Y; Tokito T; Ando S; Okamoto H
    Transl Cancer Res; 2023 Apr; 12(4):873-886. PubMed ID: 37180670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.
    Kogure Y; Saka H; Takiguchi Y; Atagi S; Kurata T; Ebi N; Inoue A; Kubota K; Takenoyama M; Seto T; Kada A; Yamanaka T; Ando M; Yamamoto N; Gemma A; Ichinose Y
    Clin Lung Cancer; 2018 Sep; 19(5):e711-e715. PubMed ID: 29861395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
    Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC.
    Katsurada N; Tachihara M; Hatakeyama Y; Koyama K; Yumura M; Kiriu T; Dokuni R; Hazama D; Tokunaga S; Tamura D; Nakata K; Yamamoto M; Kamiryo H; Kobayashi K; Tanaka Y; Maniwa Y; Nishimura Y
    Cancer Manag Res; 2020; 12():777-782. PubMed ID: 32099473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
    Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
    Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC).
    Kaplan B; Altýnbas M; Eroglu C; Karahacioglu E; Er O; Ozkan M; Bilgin M; Canoz O; Gulmez I; Gulec M
    Am J Clin Oncol; 2004 Dec; 27(6):603-10. PubMed ID: 15577439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
    Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
    Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.